---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-058031"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2024-03-04T23:59:59+00:00"
generated_at: "2026-06-05T04:42:38.202950+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "low"
source: SEC EDGAR
---

# Annexon holds virtual R&D Day focusing on Guillain-Barré Syndrome program

## Summary
- Presentation highlighted serious unmet need in Guillain-Barré Syndrome and Annexon's novel therapeutic approach.
- Webcast archive available on investor page for 30 days; CEO Douglas Love presented.
- No financial results, guidance, or clinical data disclosed in the filing.

## SEC filing metadata
- accession: 0001193125-24-058031
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2024-03-04T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000119312524058031/0001193125-24-058031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000119312524058031/d790221d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-058031
- JSON: https://secwatch.observer/filing/0001193125-24-058031.json
- Plain text: https://secwatch.observer/filing/0001193125-24-058031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.